MinorLipid-lowering agent of the fibrate class×Gabapentinoids (antiepileptics)
Updated · Methodology
Mechanism
Pregabalin is hardly metabolised: less than 2% of a dose appears in urine as metabolites and the kidneys excrete the rest unchanged. It does not bind to plasma proteins and does not inhibit drug metabolism in vitro, so pharmacokinetic interactions are unlikely (pregabalin SmPC, European Medicines Agency, EMA). Gemfibrozil inhibits CYP2C8, CYP2C9, CYP2C19 and CYP1A2, glucuronidation enzymes and the OATP1B1 transporter, and it may displace other drugs from protein binding (Lopid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Pregabalin depends on none of these pathways. Pregabalin and its class do not appear in the gemfibrozil interaction lists, and gemfibrozil does not appear in those of pregabalin (Lopid SmPC, AEMPS; pregabalin SmPC, EMA).
Symptoms
The documents describe no symptoms linked to this combination. Pregabalin most often causes dizziness and somnolence, and it can also cause peripheral oedema and weight gain. Creatine phosphokinase (CPK) elevations occur with it, and the relationship of rare cases of rhabdomyolysis to pregabalin is not completely understood (Lyrica label, US Food and Drug Administration, FDA). Gemfibrozil most often causes dyspepsia, and it can cause myositis and myopathy with muscle pain, weakness and raised CPK (Lopid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of pregabalin and gemfibrozil need no change. No document names the pair, and drugs that alter metabolism or protein binding do not affect pregabalin pharmacokinetics (pregabalin SmPC, European Medicines Agency, EMA; Lyrica label, US Food and Drug Administration, FDA). Each drug has its own instructions in its documents. Stop pregabalin if myopathy is diagnosed or suspected or if creatine phosphokinase (CPK) rises markedly, and ask patients to report unexplained muscle pain, tenderness or weakness promptly (Lyrica label, FDA). Stop gemfibrozil in case of diffuse muscle pain, muscle weakness or CPK more than 5 times the upper limit of normal (Lopid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Adjust the pregabalin dose to creatinine clearance (pregabalin SmPC, EMA). Gemfibrozil is contraindicated in severe renal impairment (Lopid SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: LOPID (gemfibrozil tablets, USP) prescribing information (2024)– FDA DailyMed, LOPID (gemfibrozil), Parke-Davis Div of Pfizer, 2024
- FDA: Lyrica (pregabalin) prescribing information (2025)– FDA label, DailyMed setid 60185c88-ecfd-46f9-adb9-b97c6b00a553, sections 5.4, 6.2
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Gemfibrozilo, Lopid 600 mg (nº registro 58832), sección 4.4 (2025)– AEMPS, CIMA, nº registro 58832 (Lopid 600 mg comprimidos recubiertos con película, Pfizer), revisión 12/2025, secciones 4.2, 4.3, 4.4, 4.5 y 5.2